NASDAQ: CRBUCaribou Biosciences Inc Stock Ownership - Who owns Caribou Biosciences?
Insider buying vs selling
Have Caribou Biosciences Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Rachel E. Haurwitz | President and CEO | 2025-03-14 | 20,000 | $1.02 | $20.40kBuy |
| Steven Kanner | Chief Scientific Officer | 2025-02-21 | 3,564 | $1.35 | $4.81kSell |
| Ruhi Ahmad Khan | Chief Business Officer | 2025-02-21 | 3,564 | $1.35 | $4.81kSell |
| Barbara G. McClung | Chief Legal Officer | 2025-02-21 | 3,564 | $1.35 | $4.81kSell |
| Sriram Ryali | Chief Financial Officer | 2025-01-29 | 17,360 | $1.42 | $24.65kBuy |
CRBU insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CRBU insiders and whales buy or sell their stock.
CRBU Shareholders
What type of owners hold Caribou Biosciences Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Blackrock Inc | 7.06% | 6,564,189 | $4.82M | Institution |
| Pfizer Inc | 5.04% | 4,690,431 | $3.45M | Institution |
| Vanguard Group Inc | 4.91% | 4,565,445 | $3.36M | Institution |
| Pfm Health Sciences LP | 4.17% | 3,876,462 | $2.85M | Institution |
| Rachel E. Haurwitz | 3.94% | 3,664,845 | $2.69M | Insider |
| Fmr LLC | 3.57% | 3,323,284 | $2.44M | Insider |
| Morgan Stanley | 2.96% | 2,749,597 | $2.02M | Institution |
| Jpmorgan Chase Co | 2.68% | 2,495,922 | $1.83M | Institution |
| Kynam Capital Management LP | 2.59% | 2,406,147 | $1.77M | Institution |
| Schonfeld Strategic Advisors LLC | 2.27% | 2,113,272 | $1.55M | Institution |
CRBU vs Biotech Stocks
Caribou Biosciences Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.